Skip to main content

Table 4 Response to PXT3003 on efficacy outcomes in HD and in PLI, with comparisons of HD versus PLI (Full Analysis Set, n = 80)

From: Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

 

Mean % of improvement

PXT3003 HD versus PLI

 

PLI

PXT3003 HD

Estimate

P-value

(n = 61)

(n = 19)

CMTNS

−3.4 (18.4)

5.2 (12.5)

8.0 (0.4;16.2)

0.042*

ONLS

−7.7 (28.5)

6.8 (18.2)

12.1 (2.0;23.2)

0.024*

6MWT (m)

7.1 (8.6)

9.9 (6.9)

2.6 (−0.73;6.1)

0.099

9HPT (s)

1.8 (11.1)

6.1 (10.6)

1.2 (−3.4;6.0)

0.33

Ankle Dorsiflexion (Nm)

33.1 (223.2)

20.4 (64.1)

5.5 (−12.8;27.7)

0.32

Grip (kg)

5.1 (17.9)

11.7 (18.1)

6.0 (−1.2;13.7)

0.088

CMAP (milliV)

19.6 (56.5)

64.2 (208.5)

6.6 (−15.8;35.1)

0.33

MCV (m/s)

4.2 (10.9)

9.0 (17.6)

2.5 (−2.4;7.7)

0.21

DML (ms)

3 (15.3)

5 (15.2)

2.2 (−5.1;10.0)

0.31

SNAP (microV)

15.9 (110.2)

5.2 (69.0)

12.0 (−23.9;64.9)

0.31

SCV (m/s)

12.7 (38.0)

30.5 (10.0)

20.1 (2.4;40.8)

0.030*

  1. Data are mean % (s.d.) of improvement for HD and for PLI after 12 months. Differences between treatment groups were assessed by Analysis of Covariance (ANCOVA) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). P-values are one-tailed. *P < 0.05; Shading = best improvement within groups. CMTNS Charcot-Marie-Tooth Neuropathy Score, ONLS Overall Neuropathy Limitations Scale, 6MWT 6-Minute Walk Test, 9HPT 9-Hole Peg Test, CMAP Amplitudes of Compound Muscle Action Potentials, MCV Motor Conduction Velocity, DML Distal Motor Latency, SNAP Amplitudes of Sensory Nerve Action Potentials, SCV Sensitive Conduction Velocity
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172